Gut bacteria can interfere with the main treatment of Parkinson's disease

Published in Microbiology

Gut bacteria can interfere with the main treatment of Parkinson's disease
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Patients with Parkinson’s Disease are treated with levodopa, which is converted into the neurotransmitter dopamine in the brain. In a study that was published on 18 January in Nature Communications, we show that gut bacteria can metabolise levodopa into dopamine. As dopamine cannot cross the blood-brain barrier, this means the bacteria can compromise the availability of the medication, even in the presence of inhibitors that should prevent the conversion of levodopa. Check it at: https://www.nature.com/articles/s41467-019-08294-y

Please sign in or register for FREE

If you are a registered user on Research Communities by Springer Nature, please sign in

Follow the Topic

Microbiology
Life Sciences > Biological Sciences > Microbiology

Related Collections

With Collections, you can get published faster and increase your visibility.

Healthy Aging

This collection welcomes submissions based on studying preclinical models, as well as population-wide and clinical studies. Studies that advance our understanding of mechanisms behind healthy aging are also welcomed. Clinical research of interest will include epidemiological studies, observational studies, longitudinal cohort studies, systematic reviews and clinical trials.

Publishing Model: Open Access

Deadline: Jun 01, 2026

Women's Health

A selection of recent articles that highlight issues relevant to the treatment of neurological and psychiatric disorders in women.

Publishing Model: Hybrid

Deadline: Ongoing